Mr. Stefan Yee has more than 35 years of experience in audit, corporate law, mergers and acquisitions, corporate finance and private equity.

Mr. Stefan Yee has more than 35 years of experience in audit, corporate law, mergers and acquisitions, corporate finance, investment banking, governance and private equity with companies as KPMG, Linklaters, the Flemish investment bank Lessius, FPIM International, Beluga (Euronext Brussels) and as the founder and CEO of the PE Group and PE Capital Group (now Arteva Capital), a Belgian privately held private equity group. Stefan is, and has been an investor and/or board member of several listed and private companies such as, amongst others, Beluga, Encare group (Mensura), AXI group, The Reference, Loomans Group, Capco, Spacewell, Dekabo group, AED Group, Banqup Group (Euronext Brussels), NRG Fitness, Robovision, Kemetyl Group, EnergyKing group or Nallian, including several healthcare related companies (Docpharma (formerly Euronext Brussels), Uteron Pharma, Imcyse, BrainM and Axiles Bionics). Stefan holds master’s degrees in law and business management from the Universities of Brussels (VUB and ULB Solvay Business School) and the University of Chicago Law School (as a BAEF Fellow).

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in.

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in several positions including country & area manager (covering major territories) and board member of the Zambon Group. He was founder and CEO of Docpharma, a Belgian based generics company that was listed on Euronext and served on different boards including Ecodis and Uteron Pharmaceuticals. He was a founding member of BIGE/IBES (Belgian Institute for Health and Economics), the B.G.A. (Belgian Generic Association), BAPIE (Belgian Association of Parallel Import and Export) and was an executive committee member and board member of the Belgian Pharmaceutical Industry Association. He also was a member of the pharmaceutical deontological commission and responsible for this commission in the industry association executive committee.

Dr. Mélanie Mestdagt is a seasoned executive with over 20 years of leadership in the biotechnology and pharmaceutical industries. She currently serves as CEO of EyeD Pharma and UniD Manufacturing, two Belgian-based companies specializing in innovative long-acting drug delivery implants. Under her leadership, the companies have grown to nearly 100 employees and secured over €70 million in combined funding, while overseeing the development of new manufacturing facilities and guiding products from early-stage research through to market authorization.

Prior to her current role, Dr. Mestdagt held successive leadership positions at EyeD Pharma and Biofinance Consulting, and previously worked at Uteron and Actavis in R&D funding and strategic coordination roles. Her career began in academia, where she earned a PhD in Biomedical and Pharmaceutical Sciences from the University of Liège and conducted oncology research supported by FNRS Télévie.

She currently serves on the boards of AWEX (Wallonia Export-Investment Agency), the European Biotech Campus (EUBC), and is Vice-President of the BioWin Health Cluster. Dr. Mestdagt brings deep expertise in translational research, industrialization, regulatory strategy, and public-private financing in health innovation.

She is a Belgian national and holds a PhD and multiple degrees in biomedical sciences from the University of Liège.

Vincent started his career in 1984 as a stockbroker at Cohen, De Greef, Van Dessel & C° in Brussels (Belgium) and later (1989) Van Dessel & C° in Antwerp (Belgium). In 1992, he joined the Brussels Stock Exchange (which became part of Euronext in 2000) as Markets and Listing Director and became member of the managing board Brussels Stock Exchanges (1998), member of the Executive Committee of Euronext NV (2000), member of the Management Board of NYSE Euronext and Chairman and CEO of NYSE Euronext Brussels (2009) and member of the Managing Board of Euronext NV and Chairman and CEO of Euronext Brussels (2014).

He served as Chairman of the Brussels Market Authority from 2000 to 2003 and was member of the Belgian Corporate Governance Committee from 2009 till 2023 and member of the Euribor Steering Committee from 2015 till 2020. In May 2024, he has been appointed member of the Board of VFB, the Federation of individual investors in Belgium and since 1st of January 2025 he serves as Chairman of this Board.

He is Licenciaat-Doctorandus in Applied Economics from the KULeuven University, Belgium and has been guest lecturer in several universities including the KULeuven, UCL, Lille University, Solvay Business School, HEC Liège Antwerp University and Paris Sorbonne.

Seasoned entrepreneur in biotech with 15+ years of experience, Revital Rattenbach is the founding CEO of 4P pharma, a clinical stage biotech specialized in drug regeneration for treating severe diseases.

Under her CEOship, 4P Pharma assembled a unique circular drug development platform which delivered 2 programs in clinical stage while nurturing a furnished preclinical pipeline. She signed multiple academic and pharma collaborations worldwide and closed series of fundraising since 4P incorporation 8 years ago.

Prior to her role at 4P, Revital was the Head of PharmaSeed Europe (2013-2014) a research organization specialized in early development where she supervised all BD activities, finance and operations.

Prior to PharmaSeed, Revital started her entrepreneurship path by co-founding Adstem, a spin-off of Sorbonne University to activate endogenous adult stem cells. Revital is board member of Biosenic, listed company on Euronext Brussels and she holds a PhD in Biology from University of Paris VI and an MBA from Sorbonne University.

Mr. Stijn Van Rompay has over 20 years of experience in leadership positions at various pharmaceutical companies.

Stijn co-founded and was the CEO of Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.

Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp and an honorary doctorate from Long Island University.

Mr. Thomas Jacobsen has over 20 years of experience in the pharmaceutical industry, with expertise in operational management, business development, licensing, and research and development.

He co-founded Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product distribution. Prior to this, he worked with Docpharma, a generics and medical-device company that was acquired by Matrix Laboratories/Mylan Laboratories, where he worked on out-licensing of Docpharma’s products. Thomas started his career in the Scandinavian-based generics company Alternova, where he was responsible for licensing, product registration and launches. Thomas holds a Master’s Degree in Pharmacy from the University of Copenhagen and a Business Degree from Copenhagen Business School.

Thomas was co_ceo of Hyloris from mid 2024 till November 2025.

Christophe Maréchal is an experienced executive with a strong background in financial and strategic leadership. With over 30 years of professional experience, he has held senior financial roles across various industries, including pharmaceuticals, EPC, telecommunications, glass manufacturing, and banking. His career includes key positions with major international organizations such as Orange and AGC, and Mithra Pharmaceuticals, providing him with valuable global exposure.

Christophe has expertise in corporate finance, equity fundraising, investor relations, mergers and acquisitions, tax planning, treasury, supply chain optimization, and financial risk management. He has developed and implemented strategies to drive long-term business growth and improve operational and financial performance.

He holds a Master of Business Administration in Commercial Engineering from the University of Liège, Belgium, and has studied econometrics at the Katholieke Universiteit Brabant in Tilburg, Netherlands.

Dr. Dietmar Aichhorn, PhD, has over 25 years of experience in various scientific roles within the pharmaceutical industry.

Over the course of his career at Sandoz, Mylan, Innovacell, ViraTherapeutics and Polpharma Biologics, Dietmar has held several senior management positions of increasing responsibilities including Head Clinical Development and Head Development. Dr. Dietmar Aichhorn is an expert in the fields of technical development, clinical development and regulatory affairs in the US, EU and other key geographies. Most recently, Dietmar had an assignment at Polpharma Biologics, where he was responsible for the clinical development of monoclonal antibodies. Dietmar has a master in chemistry from Kepler University Linz and doctorate from Vienna University of Economics and Business.

Ann De Jaeger has over 25 years of international leadership experience in legal, governance, and corporate affairs.,

Throughout her career, Ann has held senior executive and board-facing roles at multinational, listed, and family-owned companies in the FMCG and B2B sectors, including Tate & Lyle, Barco, Alpro, Danone and What’s Cooking Group. She has a strong track record in supporting business transformation, M&A, regulatory strategy, communication, and stakeholder engagement, serving as a trusted advisor to CEOs and boards on corporate governance, compliance, and risk management. Ann has played a leading role in major strategic transactions, company and product positioning, integrations, and divestitures, and has extensive experience in public affairs and ESG advocacy at European and international levels.

Ann holds a Master of Law from Ghent University, a master in business law from the University of Antwerp, and has completed several leadership courses at IMD, MIT, and Vlerick. She is also a Certified Board Director.